Free Trial
NASDAQ:ADIL

Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis

Adial Pharmaceuticals logo
$0.40 +0.01 (+2.85%)
Closing price 04:00 PM Eastern
Extended Trading
$0.39 -0.01 (-2.12%)
As of 06:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Adial Pharmaceuticals Stock (NASDAQ:ADIL)

Advanced

Key Stats

Today's Range
$0.38
$0.40
50-Day Range
$0.33
$0.47
52-Week Range
$0.22
$1.30
Volume
425,560 shs
Average Volume
3.52 million shs
Market Capitalization
$8.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75
Consensus Rating
Moderate Buy

Company Overview

Adial Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ADIL MarketRank™: 

Adial Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Adial Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Adial Pharmaceuticals has a consensus price target of $4.75, representing about 1,086.0% upside from its current price of $0.40.

  • Amount of Analyst Coverage

    Adial Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Adial Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Adial Pharmaceuticals is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Adial Pharmaceuticals is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Adial Pharmaceuticals has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Adial Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    5.63% of the outstanding shares of Adial Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently decreased by 13.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Adial Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Adial Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.63% of the outstanding shares of Adial Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Adial Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Adial Pharmaceuticals has recently decreased by 13.99%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Adial Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    16 people have searched for ADIL on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • MarketBeat Follows

    8 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 60% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.26% of the stock of Adial Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 16.41% of the stock of Adial Pharmaceuticals is held by institutions.

  • Read more about Adial Pharmaceuticals' insider trading history.
Receive ADIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ADIL Stock News Headlines

Maxim Group Upgrades Adial Pharmaceuticals (NASDAQ:ADIL) to "Buy"
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.tc pixel
Analysts Set Expectations for ADIL Q1 Earnings
Q3 EPS Estimates for ADIL Cut by Litchfield Hills Research
See More Headlines

ADIL Stock Analysis - Frequently Asked Questions

Adial Pharmaceuticals' stock was trading at $1.01 at the start of the year. Since then, ADIL shares have decreased by 60.3% and is now trading at $0.4005.

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) posted its earnings results on Wednesday, August, 13th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.22) by $0.04.

Shares of Adial Pharmaceuticals reverse split on the morning of Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Adial Pharmaceuticals (ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE).

Company Calendar

Last Earnings
8/13/2025
Today
10/08/2025
Next Earnings (Estimated)
11/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ADIL
CIK
1513525
Fax
N/A
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$1.50
Potential Upside/Downside
+1,140.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.20 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-191.31%
Return on Assets
-153.59%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.02
Quick Ratio
5.02

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.64 per share
Price / Book
0.60

Miscellaneous

Outstanding Shares
21,830,000
Free Float
20,898,000
Market Cap
$8.36 million
Optionable
No Data
Beta
1.36

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:ADIL) was last updated on 10/8/2025 by MarketBeat.com Staff
From Our Partners